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Decisions about the role of adjuvant therapy in the manage-
ment of colorectal cancer are rarely taken on the basis of
sound scientific evidence. This is not because surgeons are
capricious, but because sound scientific evidence is, unfor-
tunately, a little thin on the ground. Since the first ran-
domised trial in the UK was initiated some 15 years ago, less
than 1% of the 26,000 cases of colorectal cancer each year
have been entered into randomised clinical trials and a
similar situation exists elsewhere. A recent overview of all of
the published evidence worldwide from trials of radiotherapy
in rectal cancer identified trials involving in total only some
5,000 patients. The individual trials were all too small to
detect reliably (or refute reliably) any realistically moderate
improvement in survival and, even when combined, their
results are equivocal (Buyse et al., 1988). It is thus hardly
surprising that surgeons are divided in their views of whether
or not radiotherapy is a useful adjuvant treatment in this
disease. A similar situation exists when considering the role
of chemotherapy where, again, there is considerable uncer-
tainty about whether adjuvant chemotherapy has any effect
on mortality at all and, if it does have an effect, no consensus
about the likely size of that effect. Recently, however,
evidence that chemotherapy - usually with 5-fluorouracil (5-
FU) containing regimens - can moderately improve survival
has been accumulating. The most promising treatments that
have been examined are a 1-week post-operative infusion of
5-FU through the portal vein (Taylor et al., 1985), 18 months
systemic administration of MOF (Fisher et al., 1988; Wol-
mark et al., 1988) and a year of systemic 5-FU given in
conjunction with levamisole (Moertel et al., 1990). There is
clearly a need for a more precise definition of the effect of
adjuvant therapy on long term survival and so, in November
1989, the UKCCCR launched AXIS, an international ran-
domised trial designed to be large enough to get definite
evidence about any survival benefit of intraportal 5-FU and
of perioperative radiotherapy. Even a moderate improvement
in survival in this disease would be important because, since
colorectal cancer is so common, an improvement of 'only'
5% in 5-year survival (say from 50% to 55%) could save
many thousands of lives each year.
Perioperative radiotherapy
The primary treatment for colorectal cancer is - and will
remain - radical surgery, which is possible in as many as
70-80% of patients. Despite undergoing 'curative' surgery,
approximately one half of these patients subsequently
develop incurable recurrent disease. The 5-year survival rates
for colorectal cancer have shown little improvement over the
past 20 years and are about 80% for Dukes Stage A, about
60% for Stage B and about 30% for Stage C. Approximately
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one half of recurrences of rectal cancer occur in the pelvic
region, although local recurrence is less common in colon
cancer. In an attempt to reduce the number of local recur-
rences (and thereby to improve survival), numerous studies
have examined the effect of adjuvant pre- or post-operative
radiotherapy in rectal cancer. The published evidence from
these studies is reviewed in the AXIS protocol (1989). Five of
11 randomised trials of perioperative radiotherapy have
reported statistically significant reductions in local recurrence
in the radiotherapy arm. These are not.complete data since
some of the published studies did not report local recurrence,
and such trials are likely to have had less promising results.
Even so, taken together, previous trials do demonstrate a
reduction in the local recurrence rate of about a quarter.
But, though there is convincing evidence that local radio-
therapy can prevent local recurrence, there is as yet no firm
evidence whether or not it confers any survival benefit -
perhaps because of the inadequate numbers of patients enter-
ed into previous trials. To detect moderate (say 5-10%)
improvements in 5-year survival reliably, trials need to recruit
several thousand patients. Previous trials have considerably
underestimated the numbers of patients needed, usually
because of an over-optimistic estimate of the likely benefit of
treatment. One way of overcoming the problem of inade-
quate numbers in individual trials is to conduct a systematic
overview (or meta-analysis) of the data from all trials that
have addressed a particular therapeutic question. This ap-
proach has been used to assess the impact of adjuvant
therapy in breast cancer (Early Breast Cancer Trialists'
Collaborative Group, 1988 & 1990) and was used by Buyse
to combine the randomised evidence from published colorec-
tal cancer trials (Buyse et al., 1988). Since that overview,
some more data have become available and an update of the
Buyse overview (Figure 1) suggests that radiotherapy may
reduce mortality by about 10%. However, this difference is
of marginal statistical significance and the data are compati-
ble with radiotherapy having no material effect on survival
or, alternatively, reducing mortality by as much as 20%. A
10 or 20% mortality reduction would represent a consider-
able saving in lives given the high incidence of the disease
(10,000 cases of rectal cancer/year in the UK alone).
Systemic chemotherapy
Adjuvant systemic chemotherapy has been studied in more
than 20 randomised trials and, again, an overview of the
available data from randomised trials suggests that adjuvant
chemotherapy may reduce mortality by about 10 or 15%
(Figure 2). Most of the regimens studied included 5-FU,
either alone or in combination with other agents. As with the
radiotherapy overview, the confidence limits range from
almost no difference to a 20% reduction in the odds of
death. Even when the data are combined in this way, there
remains some uncertainty about whether systemic
chemotherapy really does have any effect on long-term mor-
tality and, if so, about the size of the effect.
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Deaths/no. entered
Radiotherapy Control O-E Variance
Odds ratioa comparing treatment
with control mortality rates
I (and c.i.)
Pre-operative Radiotherapy
VASOG-20
Yale
Toronto
MRC 1
20 Gy 225/347 251/353 -11.0 38.1
40 Gy 9/15 11/16 -0.7 1.8-
5 Gy 46/60
5/20 Gy 318/549
EORTC-40761 34.5 Gy 55/201
VASOG-28
Stockholm
Northwest
MRC 2
31.5 Gy 121/180
25 Gy 147/351
25 Gy 83/143
40 Gy 60/129
52/65 -1.0 5.3
166/275 -4.5 44.5
61/209 -1.9 20.8
114/181 3.8 20.6
140/343 1.8 42.1
84/141 -1.1 17.3
73/132 -5.7 16.4
* Total pre-operative 1064/1975 952/1715 -20.2 206.9
Postoperative Radiotherapy
Denmark 50 Gy 105/244 104/250 1.8 30.2
GITSG-7175 40 Gy 49/101 63/110 -4.6 13.2
NSABP R-01 46.5 Gy 113/184 116/184 -1.5 21.7
MRC 3 40 Gy 23/180 39/189 -7.2 12.9
* Total postoperative 290/709 3221733 -11.6 78.0
.
=1
9% ± 7
i-
*1
14% ± 11
11% ± 6
0.0 0.5 1.0 1.5 2.0
Treatment better I Treatment worse
Treatment effect 2P<0.06
aFor each trial the observed odds reduction in the figures is represented by a black square, with its
99% confidence interval as a horizontal line. A diamond shape represents the odds reduction and 95%
confidence interval for the overview of the individual trials. (See EBCTCG 1988, 1990 for details of
statistical calculations). bData derived from Buyse et al., 1988 except for MRC 1, MRC 2, MRC 3 (MRC
Rectal Cancer Working Party, 1988), Stockholm (Stockholm Rectal Cancer Group, 1987), Northwest
(North West of England Rectal Cancer Group, 1989) and NSABP R-01 (Fisher et al., 1988).
Figure 1 Mortality in trials comparing adjuvant radiotherapy with no radiotherapy (including trials with identical chemotherapy
for both treatment and control groups)
The data shown in Figure 2 are compatible with all of the
chemotherapy regimens having broadly similar effectiveness
although, of course, some could well be more effective than
others. Because the evidence for a survival benefit of
chemotherapy only just reaches the conventional level of
significance, there are considerable statistical problems in
identifying which, if any, of the several chemotherapy
regimens studied is the most effective. For example, even the
very striking reduction in mortality of almost a third seen in
the recent intergroup trial of 5-FU and levamisole (Moertel
et al., 1990) is statistically compatible with the overall 14%
reduction in the odds of death seen when all the systemic
chemotherapy trials are combined (dotted line in Figure 2). It
is therefore possible that a moderate effect of 5-FU may have
been inflated by the play of chance in this study. The addi-
tion of levamisole to 5-FU does not improve the response
rate in advanced colorectal cancer (Buroker et al., 1985) and
so, in the absence of any convincing biological rationale for a
synergistic effect of levamisole and 5-FU, the data-derived
hypothesis of synergy between these two drugs in stage C
colon cancer should be viewed with caution. Although it now
appears that adjuvant systemic chemotherapy may well
moderately improve survival, these treatment regimens do
have disadvantages. They are associated with considerable
toxicity and usually involve a prolonged period of treatment,
typically of about a year. There remains doubt about wheth-
er the likely benefit of systemic chemotherapy outweighs the
disadvantages and so, at the moment, it seems premature to
abandon no-treatment arms in current or future colorectal
cancer trials.
Intraportal chemotherapy
In an attempt to target chemotherapy and to reduce toxicity,
several recent trials have administered 5-FU directly into the
portal venous circulation in the immediate post-operative
period. The liver is the most common site for distant recur-
rence of colorectal cancer and about one third of resected
patients will develop liver metastases. Since metastases in the
liver presumably arise via blood flow through the portal vein,
intraportal 5-FU infusion might permit ready access of the
drug to small liver deposits in a way that systemic chemo-
therapy might not. This technique has considerable practical
Trialb
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Triala
Treatment Deaths/no. entered
and duration Chemo. Control O-E Var
Prolonged sIngle-agent CTX
Chicago N Mustard 5/31 7/31 -1.0 2.5 1 year
VASOG-19a 9FU 129/193 148/205 -5.3 21.1 7weeks
VASOG-19b 5FU 40142 41/42 -0.5 0.7 indefinitely
VASOG-FUDR loxurJ'dine 233/352 239/352 -3.0 38.9
Richmond 5FU 31/102 33/101 -1.2 11.0 year
VASOG-23 5FUA- 218/334 242/343 -8.9 36.9 indefinitely
Glasgow 5FU 3/16 2/19 0.7 1.1
year
COG 5FU 69/151 81/168 -2.0 19.9 1year
Sweden 3FU 104/216 98/205 0.4 26.3 mUonths
Slough one 75/139 75/133 -1.7 16.9
Exeter 5FU 30/68 28/68 1.0 8.4
8weeks
Leicester
c 5FU 22/42 20/45 1.7 5.5
6months
INT-0035 5FU 78/304 109/310 -14.6 32.6
year
* Subtotal: single agents 1037/1990 1123/2022 -34.4 221.7
Prolonged multiple-agent CTX
VASOG-27 $FU+MeCCNU 148/327 160/318 -8.1 40.3 1 year
GITSG-6175 5FU+MeCCNU 70/156 71/159 0.2 19.5
16 months
Vienna 5FU+tMMC+AraC 25/59 21/62 2.6 7.2
3monitns
GITSG-7175 5FU+MeCCNU 30/58 37/62 -2.4 7.5
18 monaths
SWOG-7510 5FU+MeCCNU 48/95 48/94 -0.3 11.9
year
NSABP R-01 ?gU+V+PeCCNU 78/187 95/184 -9.2 23.1 montns
NSABP C-01 ?gU+V/+eCCNU 141/358 162/383 -5.4 44.8 18montns
* Subtotal: multiple agents 540/1240 594/1262 -22.6 154.3
* TOTAL: All published trials 1577/3230 1717/3284 -57.0 376.0
O.C
Test for heterogeneity: X219= 11.6; NS
Odds ratiob comparing treatment
with control mortality rates
r. (and 95% c.i.)
.
-.-
-u-h
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-
I.a
*
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14% ±6
14% ± 7
14% ±5
0 0.5 1.0 1.5 2.0
Treatment better Treatment worse
Treatment effect 2P<0.003
aData from Buyse et al., 1988 except for INT-0035 (Moertel et al., 1990) and NSABP R-01 (Fisher et
al., 1988) and NSABP C-01 (Wolmark et al., 1988). bSee footnote to Figure 1. COnly deaths due to
colorectal cancer published.
Figure 2 Mortality in published trials comparing prolonged adjuvant systemic chemotherapy with no chemotherapy (including
trials with identical radiotherapy for both treatment and control groups)
advantages over systemic chemotherapy: it involves the
surgeon in very little extra work, the cytotoxic course is short
(just one week), it has relatively few side-effects, and does not
need the patient to be referred to a specialist medical onco-
logist. The first randomised trial of this treatment reported a
highly significant improvement in survival (Taylor et al.,
1985). The authors concluded that further studies were
needed to confirm this benefit, and at least eight subsequent
studies have been undertaken. The available data (including
crude estimates where full data have not been published)
were summarised in the AXIS protocol (1989). Since then,
further encouraging results from a large NSABP study (Wol-
mark et al., 1990) and from a Dutch study (Wereldsma et al.,
1990) have been published. The current evidence from portal
vein infusion trials - including estimates where full data are
not available - is shown in Figure 3. Although the subse-
quent trials have failed to confirm the size of the mortality
reduction reported by Taylor et al. (1985), they do suggest
that a short infusion through the portal vein could well
confer a survival benefit at least as great as prolonged
systemic chemotherapy. However, this overview must be
treated with some caution because the data are not firm, the
proportion of patients excluded after randomisation in some
studies is unusually high, some studies have shown reduc-
tions in liver metastases while others have not and there are
conflicting results on the stage and site of tumour most likely
to benefit. Nevertheless, there can be no doubt about the
considerable promise of this relatively simple adjuvant treat-
ment.
AXIS - a large simple trial
These overview analyses of radiotherapy and portal vein
infusion of 5-FU present clinicians with a real challenge. If
these treatments really do improve survival, even moderately,
a considerable number of lives can be saved each year. But,
in order to be certain about the effect, the treatments need to
be studied in thousands rather than in hundreds of patients.
On the current evidence, portal vein infusion of 5-FU
appears to be at least as effective as systemic 5-FU and
levamisole - and is arguably more promising. Moreover, the
human and economic advantages of a treatment that is com-
pleted in I week with minimal morbidity are considerable. It
is clear that a really large trial that will provide a definite
answer is warranted but previous experience shows that
cancer treatment trials do not readily accrue such numbers.844 R. GRAY et al.
Trial
(Reference)
First trial
Deaths / No. Entered
Treatment Control
Liverpool/Southampton 26/117
(Taylor etal., 1985)
Subsequent trials
Australia/NZ 18/85
(Gray, 1990)
SAKK b 66/236
(Metzger etaL., 1987)
Rotterdam 28/99
(Wereldsma eta!. 1990)
NCCTG/MAYO 37/110
(Beart, 1990)
NSABP c 65/438
(Wolmark etal.. 1990)
O-E Variance
Odds Ratioa Comparing Treatment
with Control Mortality Rates
(& 95% c.i.)
54/127 -12-4 13-5 - --
29/84 -5-6 85 - I-------
88/233 -11 5 259 -
35/102 -3 0 109 -
32/109 23 119
85/461 -8.1 31-3
* Subtotal: subsequent only
214/968 269/989 -25-9
* All trials
88-4
240/1085 323/1116 -38-3 101-9
0-0 0-5 1-0 1.5
Treatment better Treatment worse
Treatment effect 2P<0.0002
Test for heterogeneity: X25 = 9.2; NS
aSee footnote to Figure 1. b5-FU + Mitomycin-C. cEstimated from published data.
Figure 3 Mortality estimates in colorectal cancer trials comparing portal vein infusion of 5-FU (sometimes in conjunction with
Mitomycin-C) with no adjuvant treatment.
How can AXIS recruit the substantial numbers of patients
needed?
There are three important ways in which AXIS differs
from previous colorectal cancer trials. First and foremost, the
trial has been designed to be so streamlined that it is prac-
ticable for clinicians from hospitals with no resources spare
for research to participate. The trial could hardly be simpler.
There are no complicated forms. A simple, free-phone call to
the trials office is all that is required to enter a patient. A
small amount of data is collected over the phone at the time
of randomisation. Subsequently, all the surgeon and - if
appropriate - the radiotherapist need to do is each complete
one single-sided discharge form. Thereafter, follow-up is
limited to one brief form (covering all patients) per year. No
extra tests are required before the patient can be randomised
and no additional clinic visits are needed for follow-up. A
video describing the trial and showing the various techniques
for portal vein infusion has been produced. The aim is that it
should be almost as straightforward to enter patients into the
trial as it would be to treat them in an uninformative ad hoc
manner.
Second, to accommodate heterogeneous clinical opinion
and variable resource availability, considerable flexibility in
the treatment schedules is allowed. In particular, radio-
therapy can be pre- or post-operative and, provided a reason-
ably radical dose is used, the fractionation schedule can be
according to local practice. Pre-operative radiotherapy delays
surgery by some 2 to 6 weeks, but is associated with little
morbidity and may allow more limited resections, perhaps
reducing the need for colostomies and avoiding some of the
urinary and sexual dysfunctions (James et al., 1990). The
morbidity of post-operative radiotherapy is higher because,
after surgery, the pelvis often contains small bowel which is
rarely irradiated during pre-operative treatment. Post-opera-
tive radiotherapy does, however, allow the selection of
patients with advanced, but operable tumours and toxicity
can be minimised by carefully limiting high radiation doses
to the posterior pelvis and by treating patients in the prone
position. There is little evidence from previous trials to
indicate whether pre- or post-operative treatment is likely to
be more effective and so either treatment is allowed.
Finally, eligibility is defined not by the protocol but by the
clinician's own judgement - which in itself may be dependent
on local factors such as shortage ofjunior staff or of equip-
ment which are beyond his control. For example, he may be
certain about the benefit - or lack of benefit - of radio-
therapy in one group of patients, whom he would not ran-
domise, but uncertain in another group whom he would. Or,
local constraints on the availability of radiotherapy may
mean that he can randomise a patient for intraportal 5-FU,
but not for radiotherapy. Or, he may feel that 5-FU is
potentially interesting in younger patients, but not for very
old patients. Similarly, some surgeons are convinced that
portal vein infusion would be an inappropriate treatment for
Dukes' A tumours - others are not so sure. Eligibility criteria
in AXIS are intentionally loose, so that the clinicians' own
uncertainty about what treatment is appropriate for a partic-
ular patient is the deciding factor for eligibility. Depending
on the view of the participating clinicians a very wide range
of patients may be entered. While this might seem to weaken
the trial (and it is difficult to persuade many clinicians that it
will not) it is, in fact, a positive strength. Given sufficient
numbers, a wide range of patients will not only answer
whether treatment is of any benefit but also, if it is of benefit,
will help identify which type of patient is most likely to
benefit.
There is certainly consensus on the need for AXIS. The
King's Fund Consensus Conference on Colorectal Cancer
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(BMJ, 1990) held in London recommended that 'surgeons
enter suitable patients into the AXIS national trial'. The US
National Institutes of Health Consensus meeting (J. Natl
Cancer Inst., 1990) concluded that continued clinical trials
were essential to define the optimal adjuvant therapy and
entry into these trials was 'highly encouraged'. They also
recommended that in view of the improved survival results,
immediate postoperative chemotherapy needs further investi-
gation. More controversially, they recommended that suitable
Stage C colon cancer patients unable to enter a clinical trial
should be offered 5-FU and levamisole and that Stage B and
C rectal cancer patients should receive combined chemo-
therapy and radiation therapy. These recommendations have
already been widely adopted by US clinicians and the use of
adjuvant treatments for colorectal cancer is likely to become
more commonplace in the UK also over the next few years.
We urgently need AXIS to succeed to get better evidence on
the precise role of radiotherapy and on whether portal vein
infusion of 5-FU can confer similar - or greater - survival
benefits than more prolonged and complex systemic chemo-
therapy regimens. Clearly this is an important question for
UK Surgeons, and already more than 500 patients have been
entered.
What are the costs of participating in AXIS? There is
almost no extra work involved for collaborating clinicians.
The side effects of portal vein infusion of 5-FU are few, and
no increase in post-operative mortality has been reported.
The costs of not participating could be considerably higher if
treatment for colorectal cancer continues to be given on an
uninformative ad hoc basis because of a lack of firm evidence
about the value of adjuvant therapy.
The AXIS trial is fundedjointly by the Cancer Research Campaign,
the Imperial Cancer Research Fund and the Medical Research Council.
Protocols and further information about AXIS are available
from Lore Garten, MRC Cancer Trials Office, I Brooklands
Avenue, Cambridge CB2 2BB. (Tel. 0223 311110).
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